Effect of sulphonylurea on glucose-stimulated insulin secretion in healthy and non-insulin dependent diabetic subjects: a dose-response study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9200299 Publication Model: Print Cited Medium: Print ISSN: 0940-5429 (Print) Linking ISSN: 09405429 NLM ISO Abbreviation: Acta Diabetol Subsets: MEDLINE
    • Publication Information:
      Publication: Berlin : Springer Verlag
      Original Publication: Berlin : Springer International, c1991-
    • Subject Terms:
      Blood Glucose/*metabolism ; Diabetes Mellitus, Type 2/*physiopathology ; Glipizide/*pharmacology ; Glucose/*pharmacology ; Insulin/*metabolism; Adult ; Analysis of Variance ; C-Peptide/blood ; C-Peptide/metabolism ; Diabetes Mellitus, Type 2/blood ; Female ; Glucose Clamp Technique ; Humans ; Insulin/blood ; Insulin Secretion ; Kinetics ; Male ; Middle Aged ; Reference Values ; Time Factors
    • Abstract:
      The effect of a rapid-acting sulphonylurea, glipizide, on the dose-response relationship between the beta-cell response (insulin and C-peptide secretion) and the ambient plasma glucose concentration was examined in 12 healthy and 6 non-insulin-dependent diabetic subjects. The subjects participated in two sets of experiments which were performed in random order: (A) four hyperglycaemic clamp studies, during which the plasma glucose concentration was raised for 120 min by 1 (only in healthy subjects), 3, 7, and 17 mmol/l; and (B) the same four hyperglycaemic clamp studies preceded by ingestion of 5 mg glipizide. All subjects participated in a further study, in which glipizide was ingested and the plasma glucose concentration was maintained at the basal level. In control subjects in the absence of glipizide, the first-phase plasma insulin response (0-10 min) increased progressively with increasing plasma glucose concentration up to 10 mmol/l, above which it tended to plateau. Glipizide augmented the first-phase insulin response without changing the slope of the regression line relating plasma insulin to glucose concentrations. The second-phase plasma insulin response (20-120 min) increased linearly with increasing hyperglycaemia (r = 0.997). Glipizide alone increased the plasma insulin response by 180 pmol/l. A similar increase in plasma insulin response following glipizide was observed at each hyperglycaemic step, indicating that glipizide did not affect the sensitivity of the beta-cell to glucose. First-phase insulin secretion was reduced in the type 2 (non-insulin-dependent) diabetic patients, and was not influenced by glipizide.(ABSTRACT TRUNCATED AT 250 WORDS)
    • References:
      J Clin Endocrinol Metab. 1979 Jun;48(6):946-54. (PMID: 447800)
      J Clin Endocrinol Metab. 1976 Jun;42(6):1168-75. (PMID: 932179)
      Diabetes Care. 1987 Nov-Dec;10(6):671-8. (PMID: 3123184)
      J Clin Endocrinol Metab. 1982 Aug;55(2):321-8. (PMID: 7045153)
      Diabetes. 1977 Apr;26(4):314-21. (PMID: 849812)
      Metabolism. 1989 Aug;38(8):767-72. (PMID: 2668699)
      Diabetologia. 1985 Nov;28(11):809-14. (PMID: 3936738)
      Diabetes. 1984 Sep;33(9):838-45. (PMID: 6432610)
      Ann Intern Med. 1968 Apr;68(4):757-69. (PMID: 4868334)
      J Chromatogr. 1979 Dec 1;164(4):541-6. (PMID: 44300)
      Diabetes. 1967 Jul;16(7):487-92. (PMID: 6028757)
      Metabolism. 1990 Dec;39(12):1292-9. (PMID: 2246970)
      Am J Physiol. 1986 Jun;250(6 Pt 1):E655-61. (PMID: 3521312)
      Diabetologia. 1990 Nov;33(11):675-80. (PMID: 2076799)
      Diabetologia. 1975 Dec;11(6):541-8. (PMID: 1239396)
      Biochem J. 1963 Jul;88:137-46. (PMID: 13952078)
      Diabetes. 1987 Nov;36(11):1320-8. (PMID: 3117609)
      J Clin Endocrinol Metab. 1972 Oct;35(4):585-91. (PMID: 5052977)
      Diabetes Metab Rev. 1986;2(3-4):297-313. (PMID: 3527617)
      J Clin Endocrinol Metab. 1981 Dec;53(6):1256-62. (PMID: 7028776)
      Metabolism. 1980 Jan;29(1):23-27. (PMID: 6986011)
      Am J Physiol. 1979 Sep;237(3):E214-23. (PMID: 382871)
      J Clin Endocrinol Metab. 1989 Sep;69(3):571-6. (PMID: 2503533)
      Ann N Y Acad Sci. 1957 Jul 10;71(1):4-11. (PMID: 13459194)
      Diabetes Care. 1991 Aug;14(8):724-7. (PMID: 1954808)
      J Clin Endocrinol Metab. 1976 Feb;42(2):222-9. (PMID: 1262429)
      Lancet. 1989 Jul 15;2(8655):129-30. (PMID: 2567896)
      Eur J Clin Pharmacol. 1988;35(1):31-7. (PMID: 3065086)
      Metabolism. 1988 Jun;37(6):526-34. (PMID: 3287091)
    • Grant Information:
      AM-24092 United States AM NIADDK NIH HHS; F05-TWO-3451 United States TW FIC NIH HHS; RR 125 United States RR NCRR NIH HHS
    • Accession Number:
      0 (Blood Glucose)
      0 (C-Peptide)
      0 (Insulin)
      IY9XDZ35W2 (Glucose)
      X7WDT95N5C (Glipizide)
    • Publication Date:
      Date Created: 19910101 Date Completed: 19920309 Latest Revision: 20191028
    • Publication Date:
      20221213
    • Accession Number:
      10.1007/BF00579720
    • Accession Number:
      1777653